NASDAQ:LAB - Nasdaq - US34385P1084 - Common Stock - Currency: USD
1.01
-0.05 (-4.72%)
The current stock price of LAB is 1.01 USD. In the past month the price decreased by -9.01%. In the past year, price decreased by -59.27%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 18.39 | 152.06B | ||
DHR | DANAHER CORP | 25.49 | 135.91B | ||
A | AGILENT TECHNOLOGIES INC | 20.73 | 31.91B | ||
IQV | IQVIA HOLDINGS INC | 12.42 | 24.28B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 28.56 | 24.01B | ||
WAT | WATERS CORP | 29.32 | 20.78B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.75 | 15.15B | ||
ILMN | ILLUMINA INC | 24.7 | 13.02B | ||
RVTY | REVVITY INC | 18.34 | 10.66B | ||
ICLR | ICON PLC | 9.5 | 10.35B | ||
QGEN | QIAGEN N.V. | 19.62 | 9.77B | ||
TEM | TEMPUS AI INC | N/A | 9.55B |
Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. The company is headquartered in South San Francisco, California and currently employs 818 full-time employees. The company went IPO on 2011-02-10. The firm's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The firm works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. The company offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
STANDARD BIOTOOLS INC
2 Tower Place, Suite 2000
South San Francisco CALIFORNIA US
Employees: 816
Phone: 16502666000
The current stock price of LAB is 1.01 USD. The price decreased by -4.72% in the last trading session.
The exchange symbol of STANDARD BIOTOOLS INC is LAB and it is listed on the Nasdaq exchange.
LAB stock is listed on the Nasdaq exchange.
7 analysts have analysed LAB and the average price target is 2.42 USD. This implies a price increase of 139.85% is expected in the next year compared to the current price of 1.01. Check the STANDARD BIOTOOLS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
STANDARD BIOTOOLS INC (LAB) has a market capitalization of 383.62M USD. This makes LAB a Small Cap stock.
STANDARD BIOTOOLS INC (LAB) currently has 816 employees.
STANDARD BIOTOOLS INC (LAB) has a resistance level at 1.02. Check the full technical report for a detailed analysis of LAB support and resistance levels.
The Revenue of STANDARD BIOTOOLS INC (LAB) is expected to decline by -1.2% in the next year. Check the estimates tab for more information on the LAB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LAB does not pay a dividend.
STANDARD BIOTOOLS INC (LAB) will report earnings on 2025-07-29.
STANDARD BIOTOOLS INC (LAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).
The outstanding short interest for STANDARD BIOTOOLS INC (LAB) is 4.99% of its float. Check the ownership tab for more information on the LAB short interest.
ChartMill assigns a fundamental rating of 3 / 10 to LAB. LAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months LAB reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 65.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -22.91% | ||
ROE | -29.2% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to LAB. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 48.58% and a revenue growth -1.2% for LAB